An independent two-stage DCF analysis by a frontier AI model.
Regeneron's valuation is fundamentally anchored in its proprietary VelociSuite technologies, which consistently deliver a higher probability of success in drug discovery than industry averages. The company is not merely a collection of current assets but a proven engine for generating future blockbusters. The ongoing phenomenal success of Dupixent, in partnership with Sanofi, provides massive, growing cash flows that fund this continuous innovation cycle.
While the market often focuses intensely on the competitive dynamics surrounding Eylea, Regeneron's deep pipeline in oncology, hematology, and genetic medicines is underappreciated. The company's ability to successfully commercialize new, high-value therapeutics provides a clear path to sustained free cash flow generation, suggesting the current market price may undervalue its long-term potential.
An 8.0% growth rate is projected. This balances the expected continued high growth of Dupixent and the oncology portfolio against the mature phase of the standard Eylea franchise and the inherent risks of pipeline development.
A 9.0% discount rate is utilized, reflecting the typical risk profile of the biotechnology sector, including clinical trial uncertainty and regulatory risks, despite Regeneron's established commercial base.
A 2.5% terminal growth rate assumes that Regeneron's discovery engine will continue to produce viable therapeutics long-term, growing slightly faster than the broader economy.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 1.5% | $1,046.50 | $885.50 | $767.43 | $677.15 | $605.87 |
| 2.0% | $1,151.15 | $959.29 | $822.25 | $719.47 | $639.53 |
| 2.5% | $1,279.06 | $1,046.50 | $885.50 | $767.43 | $677.15 |
| 3.0% | $1,438.94 | $1,151.15 | $959.29 | $822.25 | $719.47 |
| 3.5% | $1,644.50 | $1,279.06 | $1,046.50 | $885.50 | $767.43 |
■ Undervalued vs current price ■ Overvalued vs current price
Regeneron boasts a formidable economic moat built on its powerful proprietary drug discovery platforms and a strong portfolio of commercialized therapeutics, notably Dupixent and Eylea. The company's consistent R&D productivity and strategic partnerships drive robust competitive momentum. While patent cliffs and biosimilar competition present ongoing risks, its deep pipeline offers significant potential for future growth.
Regeneron maintains strong competitive momentum, propelled by the continued exceptional growth of Dupixent and the successful transition to high-dose Eylea.
The company's moat is wide, protected by extensive intellectual property, high R&D barriers to entry, and proprietary technology platforms like VelociSuite.
Market sentiment is generally bullish, focused on the pipeline's potential and the ongoing success of key franchises, though tempered by patent expiry concerns.
This rate anticipates that the rapid expansion of Dupixent and the emergence of new oncology products will more than offset any revenue degradation from the aging standard Eylea franchise.
The model is highly sensitive to the success rate of the pipeline. Significant clinical failures in late-stage trials or faster-than-expected erosion of Eylea's market share due to biosimilars would negatively impact the valuation.
The financial model accounts for the profit-sharing economics of the Sanofi collaboration on Dupixent and Kevzara, focusing on the net cash flows Regeneron retains.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.